Balchem Q3 sales rallies 8.6% to $290.7M as earnings increase 16%
Key points
- Balchem reported third-quarter 2026 net sales of $290.7 million, up 8.6% year over year, while GAAP net earnings increased 16% to $46.7 million.
- Diluted earnings per share rose to $1.46 from $1.24, while adjusted EBITDA increased 12.4% to $80.3 million.
- All three reporting segments recorded sales growth, gross margin expanded to 36.4%, and operating cash flow reached $69.8 million.
Balchem Corporation (NASDAQ: BCPC) reported third-quarter 2026 net sales of $290.7 million, up 8.6% year over year, as revenue and operating earnings grew across all three reporting segments.
GAAP net earnings increased 16% to $46.7 million from the prior-year period, while diluted earnings per share rose to $1.46 from $1.24.
Adjusted EBITDA, a non-GAAP measure of earnings before interest, taxes, depreciation and amortization, increased 12.4% to $80.3 million.
Human Nutrition and Health sales grew 8.1%, while Animal Nutrition and Health sales increased 11.7%.
Specialty Products sales rose 4.5%, reflecting growth across Balchem's business portfolio.
Gross margin expanded to 36.4% from 35.7%, despite higher costs for certain manufacturing inputs.
Operating expenses increased to $43.3 million from $40.9 million.
Cash generation remained positive during the quarter, with operating cash flow of $69.8 million and free cash flow of $57.9 million.
Balchem also made $28 million in net debt payments during the period.
For the first nine months of 2026, sales reached $845.364 million, compared with $773.544 million in the corresponding period of 2025.
Balchem develops and manufactures specialty ingredients and nutritional products for human nutrition, animal nutrition and health, and selected industrial and specialty applications.
Its latest results reflect broad-based sales growth, improved profitability and continued debt reduction.
